Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: The CLASS study

Gian M. Rossolini, Matthew S. Dryden, Roman S. Kozlov, Alvaro Quintana, Robert K. Flamm, Jörg M. Läuffer, Emma Lee, Ian Morrissey

Research output: Contribution to journalArticle

Abstract

Objectives: To assess the in vitro activity of ceftobiprole and comparators against a recent collection of Gram-positive and Gram-negative pathogens, in order to detect potential changes in susceptibility patterns, and to evaluate the Etest assay for ceftobiprole susceptibility testing. Methods: Contemporary Gram-positive and Gram-negative isolates (excluding extended-spectrum β-lactamase-producing isolates) from across Europe and the Middle East were collected, and their susceptibility to ceftobiprole, vancomycin, teicoplanin, linezolid, ceftazidime and cefepime was assessed using the Etest method. Quality testing [using Etest and broth microdilution (BMD)] was conducted at a central reference laboratory. Results: Some 5041 Gram-positive and 4026 Gram-negative isolates were included. Against Gram-positive isolates overall, ceftobiprole had the lowest MIC 50 (0.5 mg/L), compared with 1 mg/L for its comparators (vancomycin, teicoplanin and linezolid). Against methicillin-resistant Staphylococcus aureus, all four agents had a similar MIC 90 (2 mg/L), but ceftobiprole had a 4-fold better MIC 90 (0.5 mg/L) against methicillin-susceptible strains. Only 38 Gram-positive isolates were confirmed as ceftobiprole resistant. Among Gram-negative strains, 86.9%, 91.7% and 95.2% were susceptible to ceftobiprole, ceftazidime and cefepime, respectively. Pseudomonas aeruginosa was less susceptible to all three antimicrobials than any other Gram-negative pathogen. There was generally good agreement between local Etest results and those obtained at the reference laboratory (for ceftobiprole: 86.8% with Gram-negatives; and 94.7% with Gram-positives), as well as between results obtained by BMD and Etest methods (for ceftobiprole: 98.2% with Gram-negatives; and 98.4% with Gram-positives). Conclusions: Ceftobiprole exhibits in vitro activity against a wide range of Gram-positive and Gram-negative pathogens, including multidrug-resistant strains. No changes in its known susceptibility profile were identified.

Original languageEnglish
Article numberdkq397
Pages (from-to)151-159
Number of pages9
JournalJournal of Antimicrobial Chemotherapy
Volume66
Issue number1
DOIs
Publication statusPublished - Jan 2011

Keywords

  • Broad spectrum
  • Cephalosporins
  • Etest
  • MRSA
  • Surveillance

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: The CLASS study'. Together they form a unique fingerprint.

  • Cite this

    Rossolini, G. M., Dryden, M. S., Kozlov, R. S., Quintana, A., Flamm, R. K., Läuffer, J. M., Lee, E., & Morrissey, I. (2011). Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: The CLASS study. Journal of Antimicrobial Chemotherapy, 66(1), 151-159. [dkq397]. https://doi.org/10.1093/jac/dkq397